News

Celebrate Psychiatric Times’ 40th anniversary with a look back at some of our previous covers.

Vanda Pharmaceuticals has submitted an NDA for approval of Bysanti for the treatment of acute bipolar I disorder and schizophrenia.

Here’s how we can best stand up to hatred…

Do you want to be featured in a future Special Report? Check out our April theme!

What percentage of 2025 psychiatric pipeline news was positive vs negative? What disease states are most prominently featured in recent research? Learn more in this exclusive article.

LB Pharmaceuticals presented additional positive data from NOVA1 exploring LB-102 in patients with acutely exacerbated schizophrenia, at the 2025 Annual Congress of the Schizophrenia International Research Society.

Spinogenix announced open enrollment for the phase 2 trial of SPG302, the first synaptic regenerative approach to treat schizophrenia with the potential to improve outcomes across all symptom domains.

Yesterday marked a somber National Doctors’ Day…

Here are highlights from this week in Psychiatric Times, including positive clinical trial news for an ADHD treatment and an exclusive interview on the joint statement defending psychotropic medication safety.

In this CME article, learn more about the common neuropsychiatric sequelae of post-acute sequelae of COVID-19, the underlying neurobiological mechanisms, and evidence-based treatments and interventions.

The LGBTQIA+ community has faced marginalization and stereotyping in media, including video games. Let’s examine the intersection of identity, mental health, and video gaming.

A social psychiatrist who stays on the ethical way.

The prevalence of tobacco use in schizophrenia is over 60%—3 times that of the general population. However, the reason for the high prevalence of tobacco use in schizophrenia remains largely unknown.

Motherhood: what is truth vs idealized narrative?

Is the real March madness gambling?

"All redeeming Nature knows, You cannot stop the spring."

How do your fellow clinicians feel about ethical quandaries in psychiatry? Find out here.

Learn more about key findings on sex differences in cognition, exploring the possible causes and implications for clinical practice.

A psychiatrist reflects on the challenges we weather and the enduring search for hope and unity.

Disruptions to cognitive control, as well as to emotional processes, are implicated in a wide range of psychiatric disorders.

The FOCUS phase 3 trial of solriamfetol for the treatment of ADHD demonstrated statistically significant improvements in ADHD symptoms and disease severity.

We want to hear from you: what else can psychiatry do to address federal doubt?

Is psychiatry up to the challenge of protecting social well-being?

Cognitive symptoms affect between 85% and 94% of patients with major depressive disorder. Despite this prevalence, cognitive dysfunction often remains undertreated and inadequately addressed in routine clinical practice.

Given that individual differences exist regarding the effects of brain injury and gaps persist in the treatment continuum, challenges arise in treating individuals with acquired brain injury. Addressing these challenges can improve patient outcomes.

Remembering a psychiatrist and an activist…

Joint statements from leading psychiatric organizations voice concern about impact on patient care from executive orders and budget cuts.

Review various aspects of cognition in our latest Special Report.

Legislative and legal realities at the state and federal levels are difficult to navigate even for seasoned practitioners, and are beyond the knowledge of most families.

Check out new data from the long-term, open-label KINECT 4 study on Ingrezza capsules for the treatment of tardive dyskinesia.